1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • February 2017
  • 243 pages
  • ID: 4938302
  • Format: PDF

Summary

Table of Contents

Search Inside

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

Summary
Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet count. The exact cause of ITP is still unclear; however, the pathophysiology of the disease can be contributed by an increased destruction of platelets, a decreased production of platelets, or both. Therefore, there might be multiple causes and mechanisms that can contribute to the disease. ITP can affect patients at all ages, but pediatric patients are likely to recover spontaneously while adult patients have a higher chance to develop into a chronic condition.

It is estimated that the value of the ITP market in the 7MM in 2015 was $928M, including sales of the major branded and off-label drugs commonly prescribed for ITP patients across the 7MM. The US is the largest contributor to the 7MM, with $587M in 2015, representing 63.3% of the market share. The 5EU and Japan contributed $281M and $60M in 2015, respectively, to the major ITP markets.

ITP market to grow during in the first half of the forecast period (2015-2025); however, sales will start to decline in 2022 in the US and projects that total ITP sales in 2025 will grow to $985M at a modest overall Compound Annual Growth Rate (CAGR) of 0.6%.

Major drivers of the growth of the ITP market over the forecast period include the following -
- Increasing uptake and market penetration of marketed brands, Amgen’s Nplate (romiplostim) and Novartis’ Promacta/Revolade (eltrombopag), in both adult and pediatric ITP populations.
- Rising diagnosed prevalence of adult ITP, and hence a rising treated population.
- Launch of Rigel Pharmaceuticals’ fostamatinib, which will offer a new mechanism of action (MOA) for ITP treatment.

Companies are looking into drugs with novel MOA, which may offer hope to improve response rate and safety. It is identified that two promising approaches: spleen tyrosine kinase (Syk) inhibitors, including the Phase III fostamatinib, and CD40/CD40 ligand antagonists. As Rigel has managed to complete two pivotal Phase III trials for fostamatinib, It is expected that the drugs offering new MOAs to be essential for companies to successfully develop new ITP therapies moving forward.

The report "OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025", provides an overview of ITP, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following analysis -
- Annualized ITP therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including pediatric, adult primary, and adult secondary), forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ITP therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ITP therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global ITP therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amgen, Bristol-Myers Squibb, Eisai, Genosco, GlaxoSmithKline, Gliknik, Hansa, Hoffmann La-Roche, Immunomedics, Jiangsu Hengrui, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Merck & Co., Momenta, Novartis, PBM Capital, Pfizer, Protalex, Rigel Pharmaceuticals, UCB Biopharma.

Scope
- Overview of ITP, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized ITP therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including pediatric, adult primary, and adult secondary), forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ITP therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ITP therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global ITP therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ITP therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Immune Thrombocytopenia Market Research Report Forecast to 2023

Global Immune Thrombocytopenia Market Research Report Forecast to 2023

  • $ 4450
  • March 2019

Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023IntroductionImmune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2019

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating ...

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on